Published in Circulation on February 07, 2013
Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg (2014) 1.19
Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti Infect Ther (2015) 1.02
Letter by Rassi and Rassi regarding article, "Ten-year incidence of Chagas cardiomyopathy among asymptomatic, Trypanosoma cruzi-seropositive former blood donors". Circulation (2013) 0.97
Letter by Bestetti and Cardinalli-Neto regarding article, "Ten-year incidence of Chagas cardiomyopathy among asymptomatic, Trypanosoma cruzi-seropositive former blood donors". Circulation (2013) 0.96
Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambui Cohort Study of Aging. J Am Heart Assoc (2014) 0.94
Genome wide association study (GWAS) of Chagas cardiomyopathy in Trypanosoma cruzi seropositive subjects. PLoS One (2013) 0.85
Developments in the management of Chagas cardiomyopathy. Expert Rev Cardiovasc Ther (2015) 0.85
Accuracy of a probabilistic record-linkage methodology used to track blood donors in the Mortality Information System database. Cad Saude Publica (2014) 0.82
Anti-Trypanosoma cruzi cross-reactive antibodies detected at high rate in non-exposed individuals living in non-endemic regions: seroprevalence and association to other viral serologies. PLoS One (2013) 0.81
Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. Parasit Vectors (2016) 0.79
Pathogenesis of chagas cardiomyopathy: role of inflammation and oxidative stress. J Am Heart Assoc (2013) 0.79
Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease. Int J Cardiol (2015) 0.79
Infection with Trypanosoma cruzi and progression to cardiomyopathy: what is the evidence and is the tide finally turning? Circulation (2013) 0.78
Chagas disease research and development: Is there light at the end of the tunnel? Comput Struct Biotechnol J (2016) 0.77
Response to letters regarding article, "Ten-year incidence of Chagas cardiomyopathy among asymptomatic, Trypanosoma cruzi-seropositive former blood donors". Circulation (2013) 0.77
Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease. Int J Cardiol (2015) 0.77
Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. BMJ Open (2016) 0.77
Putting Infection Dynamics at the Heart of Chagas Disease. Trends Parasitol (2016) 0.77
Electrocardiographic and Echocardiographic Abnormalities in Chagas Disease: Findings in Residents of Rural Bolivian Communities Hyperendemic for Chagas Disease. Glob Heart (2015) 0.76
Circulating serum markers and QRS scar score in Chagas cardiomyopathy. Am J Trop Med Hyg (2014) 0.76
Contribution of the Retrovirus Epidemiology Donor Study (REDS) to research on blood transfusion safety in Brazil. Rev Bras Hematol Hemoter (2014) 0.75
The role of interleukin 17-mediated immune response in Chagas disease: High level is correlated with better left ventricular function. PLoS One (2017) 0.75
Dysregulation of Autonomic Nervous System in Chagas' Heart Disease Is Associated with Altered Adipocytokines Levels. PLoS One (2015) 0.75
Predictive factors for the progression of chronic Chagas cardiomyopathy in patients without left ventricular dysfunction. Rev Inst Med Trop Sao Paulo (2015) 0.75
Chagas' heart disease: gender differences in myocardial damage assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2016) 0.75
Likely Autochthonous Transmission of Trypanosoma cruzi to Humans, South Central Texas, USA. Emerg Infect Dis (2017) 0.75
Preclinical stem cell therapy in Chagas Disease: Perspectives for future research. World J Transplant (2013) 0.75
Mortality among blood donors seropositive and seronegative for Chagas disease (1996-2000) in São Paulo, Brazil: A death certificate linkage study. PLoS Negl Trop Dis (2017) 0.75
Chagas Heart Failure in Patients from Latin America. Card Fail Rev (2016) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol (1986) 18.40
Chagas disease. Lancet (2010) 10.25
Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr (2009) 7.69
Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med (2006) 6.00
Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA (2007) 5.22
The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion (2012) 2.69
Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol (2007) 2.39
Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation (2007) 1.99
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J (2008) 1.99
Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol (2008) 1.74
Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation (1987) 1.52
Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality. JAMA (2007) 1.47
Chagas disease: changes in knowledge and management. Lancet Infect Dis (2010) 1.46
Chagas cardiomyopathy--where do we stand after a hundred years? Prog Cardiovasc Dis (2010) 1.45
Risk of exposure to Chagas' disease among seroreactive Brazilian blood donors. Transfusion (1996) 1.30
Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction. Heart (2003) 1.24
Epidemiologic and laboratory findings from 3 years of testing United States blood donors for Trypanosoma cruzi. Transfusion (2012) 1.10
Evaluation of the performance of Brazilian blood banks in testing for Chagas' disease. Vox Sang (1998) 1.04
[The evolution of chronic chagasic cardiopathy. I. The influence of parasitemia]. Rev Soc Bras Med Trop (1993) 1.02
Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol (2010) 0.98
Morbidity and prognostic factors in chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz (2009) 0.97
[Transmission elimination of Chagas' disease by Triatoma infestans in Brazil: an historical fact]. Rev Soc Bras Med Trop (2006) 0.96
Case-control study of factors associated with chronic Chagas heart disease in patients over 50 years of age. Mem Inst Oswaldo Cruz (2007) 0.96
B-type natriuretic peptide and anthropometric measures in a Brazilian elderly population with a high prevalence of Trypanosoma cruzi infection. Peptides (2011) 0.94
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res (2009) 6.83
TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res (2010) 6.65
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
Global epidemiology of HTLV-I infection and associated diseases. Oncogene (2005) 4.77
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS (2002) 3.22
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion (2009) 2.56
Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2011) 2.53
The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J Am Coll Cardiol (2003) 2.52
Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol (2007) 2.44
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
Blood donor satisfaction and intention of future donation. Transfusion (2008) 2.34
Biospecimen repositories: are blood donors willing to participate? Transfusion (2010) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
The consequences of temporary deferral on future whole blood donation. Transfusion (2007) 2.31
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion (2008) 2.27
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
The detection of acute HIV infection. J Infect Dis (2010) 2.14
Technology preview: X-ray fused with magnetic resonance during invasive cardiovascular procedures. Catheter Cardiovasc Interv (2007) 2.12
Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion (2010) 2.06
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab (2011) 1.98
Surface modification to reduce nonspecific binding of quantum dots in live cell assays. Bioconjug Chem (2005) 1.94
A randomized trial of blood donor recruitment strategies. Transfusion (2006) 1.89
The whole is greater than the sum of its parts: hemostatic profiles of whole blood variants. J Trauma Acute Care Surg (2014) 1.88
Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2010) 1.88
The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med (2005) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection. Blood (2008) 1.88
Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis (2012) 1.86
Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion (2009) 1.85
Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety. Transfusion (2007) 1.85
Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion (2005) 1.84
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev (2004) 1.80
Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA (2006) 1.78
West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis (2006) 1.76
Factors influencing donor return. Transfusion (2007) 1.75
Dynamics of viremia in early hepatitis C virus infection. Transfusion (2005) 1.72
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Faint and prefaint reactions in whole-blood donors: an analysis of predonation measurements and their predictive value. Transfusion (2008) 1.70
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Demographic profile of blood donors at three major Brazilian blood centers: results from the International REDS-II study, 2007 to 2008. Transfusion (2009) 1.68
Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion (2004) 1.67
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses (2006) 1.67
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (2014) 1.67
Delayed adverse reactions to blood donation. Transfusion (2009) 1.67
Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis (2006) 1.65
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis (2005) 1.62
Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion (2008) 1.62
Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion (2007) 1.60
A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood (2009) 1.59
Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis (2012) 1.59
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS (2010) 1.57
Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009. J Infect Dis (2013) 1.56
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol (2005) 1.56
Duration of red blood cell storage and survival of transfused patients (CME). Transfusion (2010) 1.53